Bronnen:
1. Smolen J, Cohen S, Emery P, et al. Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. EULAR 2018. Abstract OP0035.,2. Burmester G, Kremer J, van den Bosch F, et al. A phase 3 randomised, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective jak-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic dmards. Abstract OP0036.
1. Smolen J, Cohen S, Emery P, et al. Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. EULAR 2018. Abstract OP0035.,2. Burmester G, Kremer J, van den Bosch F, et al. A phase 3 randomised, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective jak-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic dmards. Abstract OP0036.